Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00276263
Other study ID # Heresco 3 CTIL
Secondary ID 101-06
Status Withdrawn
Phase Phase 2
First received January 12, 2006
Last updated June 3, 2014
Start date August 2006
Est. completion date June 2009

Study information

Verified date June 2014
Source Herzog Hospital
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether preventative treatment with sarcosine can reduce symptoms and delay/avoid disease progression in individuals defined as being in a prodromal stage of schizophrenia.


Description:

Schizophrenia is a neurodevelopmental disorder that affects approximately 1% of the general population and continues to be one of the major challenges of modern medicine due to the tremendous human suffering and economic costs that it involves. Once the diagnosis of schizophrenia or a related chronic psychosis has been made, the majority of patients will only partially respond to presently available pharmacological treatments and will be afflicted by long-standing deficits affecting all aspects of mental functioning.

This unfavourable outcome highlights the importance of preventive treatment for schizophrenia and related psychoses. The notion of early pharmacological intervention during the prodromal phase of these disorders has a dual aim: 1) to treat active prodromal symptoms and 2) to prevent further deterioration and progression toward the full-blown disorder and chronicity. Overall, it raises the possibility of preventing, delaying or ameliorating the onset of the diagnosable disorder. This type of intervention, although already in use in other medical branches and potentially ground-breaking for mental health delivery systems, has not been systematically assessed in the past. Recently, the development of improved criteria for detecting individuals at high risk for developing schizophrenia and related psychoses, has led to the first clinical trials that assessed the role of atypical antipsychotics (i.e., risperidone and olanzapine) for these subjects. The results of these studies indicate that significant clinical benefits nay be derived from early intervention but also point to the drawbacks of exposing patients at a very early stage of illness to antipsychotic drugs that are associated with debilitating (i.e. motor, metabolic) side effects.

The overall aim of the proposed project is to assess the efficacy and safety of the N-methyl-D-aspartate glutamate receptor (NMDAR) modulator, glycine transport inhibitor sarcosine (N-methylglycine) for the treatment of individuals fulfilling schizophrenia prodromal syndromes criteria. NMDAR's dysfunction plays a cardinal role in schizophrenia pathophysiology and the establishment of neurodevelopmental deficits. During the last decade it was demonstrated that pharmacological treatment with compounds that enhance NMDAR-mediated neurotransmission due to their agonistic activity at the NMDAR-associated glycine site (e.g. glycine, D-serine) leads to significant symptom reductions in chronic schizophrenia patients. Furthermore, preliminary findings suggest that glycine treatment may also be beneficial for patients at high risk for developing schizophrenia. By increasing glycine synaptic levels, sarcosine may generate improved therapeutic effects in high risk individuals. Sarcosine is a natural amino acid that has already been shown to reduce positive, negative and cognitive symptomatology in chronic as well as acute schizophrenia patients. Advantages of sarcosine vs. glycine site agonists use include the relatively low dose required and the lack of known side effects. Synthetic compounds conceptually similar to sarcosine are presently in various stages of development by major pharmacological companies.

In the proposed project, during a three-year period, 60 individuals fulfilling prodromal criteria will be randomly entered in a 16 week parallel group, double-blind, placebo controlled trial with 2 gr/day sarcosine, with an optional 8 week open-label extension. Clinical, neurocognitive, electrophysiological, amino acids (i.e. glycine, serine, glutamate) levels and genetic assessments will be performed during the study. The specific aims of the proposed project are: 1) to assess the efficacy and safety of sarcosine as active treatment for prodromal symptoms, 2) to assess sarcosine effects in terms of relevant amino acids serum levels, neurocognitive performance and relevant brain electrophysiological parameters and 3) to supply preliminary data in regard to the capacity of sarcosine treatment to delay/prevent conversion to full blown psychotic disorder. The overall importance of the proposed project consists of its potential to lay the foundations for an innovative type of treatment for schizophrenia prodromal states.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 12 Years to 45 Years
Eligibility Inclusion Criteria:

- Treatment-seeking male or female outpatients, 12-45 years old

- Meet the definition of one or more prodromal syndromes according to the Criteria of Prodromal Syndromes (COPS) derived using the SIPS/SOPS scales.

- Possession of a level of understanding sufficient to communicate with the investigator and to understand the nature of the study

- Agreement to participate in the study and sign informed consent. Minors will be required to give written informed consent with written consent from a parent or guardian

Exclusion Criteria:

- Meeting criteria for past or current DSM-IV psychotic disorder

- Judged clinically to suffer from a psychiatric disorder (e.g. ADHD, mania, depression) that could account for the inclusion symptoms

- Judged clinically to be at suicidal or homicidal risk

- Symptoms judged clinically to be sequelae of drug or alcohol abuse

- IQ of less than 80

- Seizure disorder without a clear or resolved etiology

- Female patients who are pregnant or lactating; female patients who are not pregnant or lactating, if sexually active, must be using medically accepted means of contraception

- Taking non-protocol psychiatric medications within two weeks of randomization or depot psychiatric medications three months prior to study entry

- Individuals suffering from an unstable and/or untreated medical disorder will not be entered in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Sarcosine (N-methylglycine)
Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.

Locations

Country Name City State
Israel Department of Psychiatry, Hadassah Hospital and Community Clinics Jerusalem
Israel Ezrath Nashim - Herzog Memorial Hospital Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Herzog Hospital

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sarcosine vs. placebo in subjects at risk for developing schizophrenia:efficacy and safety. 16 weeks Yes
Primary Sarcosine is superior to placebo in the treatment of positive, negative, and cognitive (disorganized) symptoms. Safety assessed with UKU scale, vital signs measurements and laboratory parameters (SMA-20, CBC, UA) 16 weeks Yes
Primary Sarcosine vs. placebo in the treatment of neurocognitive dysfunction 16 weeks No
Secondary To assess the efficacy of sarcosine in delay/prevention of illness progression. 16 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00128479 - A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression Phase 3